Related Experiment Videos
[Fulminant acute hepatitis treated by immunologic therapy (author's transl)]
L'Ateneo Parmense. Acta Bio-Medica : Organo Della Societa Di Medicina E Scienze Naturali Di Parma
|January 1, 1976
Summary
This study explored using specific antibodies against Hepatitis B surface antigen (anti-HBsAg) for acute fulminant hepatitis. The findings suggest this immunologic therapy may be beneficial when combined with supportive treatments.
Area of Science:
- Immunology
- Hepatology
- Virology
Background:
- Acute viral hepatitis can progress to severe, malignant forms.
- Recent research highlights the role of immunological pathogenetic mechanisms in this progression.
- Understanding these mechanisms is crucial for developing effective treatments.
Observation:
- A patient with acute fulminant hepatitis was treated using immunologic therapy.
- The therapy involved specific globulins targeting Hepatitis B surface antigen (anti-HBsAg).
- This approach was based on recent findings regarding immunological mechanisms in hepatitis.
Findings:
- The patient's treatment involved specific antibodies (HBsAb) against HBsAg.
- This immunologic therapy was administered alongside symptomatic and depurative treatments.
- The experience suggests potential benefits of HBsAb therapy in acute fulminant hepatitis.
Implications:
- Specific antibodies (HBsAb) may offer a therapeutic option for acute fulminant hepatitis.
- Combining HBsAb therapy with supportive care warrants further investigation.
- While promising, this approach has limitations due to the single-case experience.